Typ-1-Diabetes - Neue Aspekte in Therapie & Technologie 2024

In 2023, epidemiological studies based on US cohorts revealed that the median age for onset of type 1 diabetes is 24 years. Furthermore, there was a high prevalence of obesity in people with type 1 diabetes. Moreover, a variety of studies have investigated the effects of using immunomodulatory drugs to maintain beta cell function. As a consequence, distinct pharmacological candidates are at an advanced stage of development. Clearly, insulin remains the cornerstone of treatment in patients with type 1 diabetes. Several studies recently focused on once-weekly basal insulin analogues. Automated insulin delivery (AID) systems have shown dramatic advances toward the use in routine care of type 1 diabetes. During the last year, several AID systems have been reported to contributing to an increased quality of life and significant improvements in the time spent in glucose target ranges, particularly in vulnerable patient groups with type 1 diabetes.